Interaction Kinetics with Transcriptomic and Secretory Responses of CD19 CAR Natural Killer Cell Therapy in CD20 Resistant Non-Hodgkin Lymphoma

We investigated the cytolytic and mechanistic activity of anti-CD19 chimeric antigen receptor natural killer (CD19.CAR.NK92) therapy in lymphoma cell lines (diffuse large B-cell, follicular, and Burkitt lymphoma), including rituximab- and obinutuzumab-resistant cells, patient-derived cells, and a hu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravi, Dashnamoorthy, Sarkar, Saheli, Purvey, Sneha, Passero, Frank, Beheshti, Afshin, Chen, Ying, Mokhtar, Maisarah, David, Kevin, Konry, Tania, Evens, Andrew M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196029/
https://www.ncbi.nlm.nih.gov/pubmed/31772298
http://dx.doi.org/10.1038/s41375-019-0663-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196029/
https://www.ncbi.nlm.nih.gov/pubmed/31772298
http://dx.doi.org/10.1038/s41375-019-0663-x

Ejemplares similares